

ASX ANNOUNCEMENT

28 November 2022

Anteris DurAVR[™] THV comparative study to investigate aortic flow physiology by cardiac MRI presented at PCR London Valves 2022

LONDON, UK and BRISBANE, Australia, Anteris Technologies Ltd (Anteris or the Company) (ASX: AVR), announced formal results of a comparative study to investigate aortic flow physiology by cardiac MRI (cMRI) in five patients who received a DurAVR™ transcatheter aortic valve (first-in-human). The study compared DurAVR™ to normal age-height-weight matched controls, other transcatheter aortic valve implants (TAVI) and patients who had surgical aortic valve replacement (SAVR).

"DurAVR™ TAVI novel leaflet design restores ascending aortic flow haemodynamics on cardiac MRI" was presented at the annual PCR London Valves 2022 Congress, 27-29 November 2022. Dr Pankaj Garg, Associate Professor in Cardiology, at the University of East Anglia and Consultant Cardiologist at Norfolk and Norwich University Hospital quantified key heart valve performance parameters in the ascending aorta using phase-contrast (PC) MRI (a noninvasive method for imaging blood and tissue velocity). These included aortic forward flow (AFF), aortic regurgitation (AR), aortic flow displacement (AFD) at peak systole and aortic flow reversal (AFR) at peak systole.

Study results demonstrated the novel leaflet design of DurAVR™ THV restored ascending aortic flow haemodynamics, whereas SAVR and other TAVI valves did not demonstrate the same physiological advantage.

"Restoration of normal laminal aortic flow is emerging as a novel target mainly to reduce energy loss in the cardiovascular system. Abnormal flow, including eccentric flow, is associated with continued aortic dilatation which will further warrant intervention. Furthermore, as TAVI is being offered to younger cohorts, restoration of normal laminar aortic flow is an important therapeutic goal. DurAVRTM THV architecture appears to restore normal aortic flow", said Dr Garg.

Anteris CEO, Wayne Paterson added: "Future studies are warranted to investigate the prognostic importance of restoration of normal aortic flow in this patient population, but this preliminary data reveals the unique design characteristics of DurAVR™ are potentially redefining how aortic heart valve performance is benchmarked".

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVRTM THV is a single-piece, native-shaped aortic heart valve replacement that addresses the needs of today's younger and more active aortic stenosis patients by delivering

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | **F** +61 1300 972 437 | **E** info.au@anteristech.com | **W** anteristech.com

Brisbane • Minneapolis • Geneva • Malaga





superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVRTM single-piece, native-shaped aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor contact

Deanne Curry GRACosway

E: investors@anteristech.com

M: +61 414 388 997

www.anteristech.com Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

LinkedIn: https://www.linkedin.com/company/anteristech

Media contact

Nick Howe GRACosway

nhowe@gracosway.com.au

M: +61 407 183 221

